Abatacept + placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Granulomatosis With Polyangiitis (Wegener's)

Conditions

Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis

Trial Timeline

Apr 25, 2015 → Dec 20, 2023

NCT ID

NCT02108860

About Abatacept + placebo

Abatacept + placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Granulomatosis With Polyangiitis (Wegener's). The current trial status is completed. This product is registered under clinical trial identifier NCT02108860. Target conditions include Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02108860	Phase 3	Completed	Apr 25, 2015	Dec 20, 2023	Granulomatosis With Polyangiitis (Wegener's)
NCT02778906	Phase 3	Completed	Nov 1, 2014	Dec 1, 2019	Arthralgia
NCT02161406	Phase 2	Completed	Sep 1, 2014	Oct 17, 2018	Diffuse Cutaneous Systemic Sclerosis
NCT02232880	Phase 2	Terminated	Aug 1, 2014	Jun 1, 2015	Hypertension
NCT01860976	Phase 3	Completed	Jun 17, 2013	Jun 30, 2020	Psoriatic Arthritis
NCT00442611	Phase 1/2	Completed	Nov 1, 2008	Jun 1, 2011	Scleroderma, Diffuse
NCT00784459	Phase 2	Completed	Oct 1, 2008	Feb 1, 2012	Atopic Asthma
NCT00533897	Phase 3	Completed	Nov 1, 2007	Feb 1, 2014	Rheumatoid Arthritis
NCT00534313	Phase 2	Terminated	Nov 1, 2007	May 1, 2011	Psoriatic Arthritis
NCT00420199	Phase 3	Completed	May 1, 2007	May 1, 2010	Active Rheumatoid Arthritis
NCT00345748	Phase 2	Completed	Jun 1, 2006	Nov 1, 2007	Rheumatoid Arthritis
NCT00124449	Phase 2	Completed	Feb 1, 2005	Apr 1, 2008	Arthritis, Rheumatoid

Competing Products

9 competing products in Granulomatosis With Polyangiitis (Wegener's)

See all competitors

Product	Company	Stage	Hype Score
NS-229 + Placebo	Nippon Shinyaku	Phase 2	52
Benralizumab	AstraZeneca	Phase 3	77
Tezepelumab + Placebo	AstraZeneca	Phase 2	52
Rituximab	Roche	Approved	85
Rituximab	Roche	Phase 2	52
Methylprednisolone + Prednisone + Rituximab	Roche	Approved	85
Avacopan + Placebo	Amgen	Phase 2/3	64
IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC)	InflaRx	Phase 2	44
IFX-1 low dose + IFX-1 high dose + Placebo	InflaRx	Phase 2	44

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved